Safety & Availability (Biologics)

This webpage was developed to provide the public with important information about the safety and availability of biological products.

Safety communications older than 2017 are available on FDA Archive.

Biologics Safety and Availability Communications

• 2024 Safety and Availability Communications
• 2023 Safety and Availability Communications
• 2022 Safety and Availability Communications
• 2021 Safety and Availability Communications
• 2020 Safety and Availability Communications
• 2019 Safety and Availability Communications (Archived)
• 2018 Safety and Availability Communications (Archived)
• 2017 Safety and Availability Communications (Archived)

---

Related Information

• MedWatch: The FDA Safety Information and Adverse Event Reporting Program
• Letters to Industry / Healthcare Providers / Clinical Investigators (Archived)
• Bovine Spongiform Encephalopathy (BSE)
• FDA's Sentinel Initiative
• CBER Biologics Effectiveness and Safety (BEST) System

Follow CBER

Division of Communication and Consumer Affairs
Office of Communication, Outreach and Development
Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave WO71-3103
Silver Spring, MD 20993-0002

ocod@fda.hhs.gov

(800) 835-4709
(240) 402-8010

For Updates on Twitter, follow @fdacber

• Resources for You (Biologics)
• About the Center for Biologics Evaluation and Research (CBER)
• Report a Problem to the Center for Biologics Evaluation & Research
• Recalls (Biologics)
• CBER-Regulated Products: Shortages and Discontinuations
• Biologics Products & Establishments